Evidence map›Paper›PMID 28389881›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.

P Foro Arnalot, O Pera, N Rodriguez, X Sanz, A Reig, I Membrive, A Ortiz, R Granados, M Algara

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

P Foro ArnalotDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain. pforo@parcdesalutmar.cat.
O PeraDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.
N RodriguezDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.
X SanzDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.
A ReigDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.
I MembriveDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.
A OrtizDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.
R GranadosDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.
M AlgaraDepartment of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine if there is an association between the incidental radiation dose to the subventricular zone and survival in patients with glioblastoma multiforme treated with surgery, radiotherapy and temozolomide. METHODS AND MATERIALS: Sixty-five patients, treated between 2006 and 2015, were included in this retrospective study. The doses (75th percentile; p75) administered to the ipsilateral, contralateral and bilateral subventricular zone were compared to overall survival and progression-free survival using Cox proportional hazards models. Covariates included: age, sex, surgery, tumor location, and concomitant and adjuvant temozolomide.

resultsMedian progression-free survival and overall survival were 11.5 ± 9.96 and 18.8 ± 18.5 months, respectively. The p75 doses to the ipsilateral, contralateral and bilateral subventrivular zone were, respectively, 57.30, 48.8, and 52.7 Gy. Patients who received a dose ≥48.8 Gy in the contralateral subventricular zone had better progression-free survival than those who received lower doses (HR 0.46; 95% CI 0.23-0.91 P = 0.028). This association was not found for overall survival (HR 0.60; 95% CI 0.30-1.22 P = 0.16). Administration of adjuvant temozolomide was significantly associated with improved progression-free survival (HR 0.19; 95% CI 0.09-0.41 P < 0.0001) and overall survival (HR 0.11; 95% CI 0.05-0.24 P = 0.001). In the subgroup of 46 patients whose O6-methylguanine-DNA methyltransferase gene promoter status was known, the methylation had no effect on either progression-free survival (P = 0.491) or overall survival (P = 0.203).

conclusionHigh-dose radiation in the contralateral subventricular zone was associated with a significant improvement in progression-free survival but not overall survival in patients treated for glioblastoma multiforme.

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsCombined Modality TherapyDacarbazineFemaleFollow-Up StudiesGlioblastomaHumansLateral VentriclesMaleMiddle AgedPrognosisRadiation DosageRetrospective StudiesSurvival RateTemozolomideAntineoplastic Agents, AlkylatingDacarbazineTemozolomideGlioblastomaRadiotherapySubventricular zone

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.